» Articles » PMID: 17070610

Circulating Endothelial Progenitor Cells in Congestive Heart Failure

Overview
Journal Int J Cardiol
Publisher Elsevier
Date 2006 Oct 31
PMID 17070610
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Endothelial progenitor cells (EPCs) circulate in the adult peripheral blood and contribute to neovascularization. EPCs are considered to be included in CD34 positive mononuclear cells (CD34+ MNCs). Kinetics of circulating EPCs in congestive heart failure (CHF) has not been fully investigated.

Methods: We determined the numbers of white blood cells (WBCs), plasma brain natriuretic peptide (BNP), serum erythropoietin, vascular endothelial growth factor (VEGF) and thrombomodulin levels in 16 mild CHF patients (NYHA I, II), 10 severe CHF patients with acute exacerbation (NYHA III, IV), and 22 control subjects. The number of CD34+ MNCs in peripheral blood was quantified by flow cytometry.

Results: The ratio of CD34+ MNCs:10(3) WBCs in mild CHF patients was higher than that in control subjects (P<0.05). Interestingly, the ratio of CD34+ MNCs:10(3) WBCs in severe CHF patients at admission was significantly lower than that in control subjects (P<0.005) or in mild CHF patients (P<0.05). Levels of BNP and erythropoietin in severe CHF patients were significantly higher than those in mild CHF patients. However, VEGF and thrombomodulin levels were not different between mild and severe CHF patients. In addition, the ratio of CD34+ MNCs:10(3) WBCs in severe CHF patients increased in proportion to the amelioration of CHF during hospitalization, and this increase correlated with the decrease in BNP level.

Conclusions: The ratio of CD34+ MNCs:10(3) WBCs was decreased in severe CHF. These findings suggest that impaired EPC recruitment might be involved in the pathophysiology of severe CHF.

Citing Articles

Beneficial Role of Vitamin D on Endothelial Progenitor Cells (EPCs) in Cardiovascular Diseases.

Sen A, Vincent V, Thakkar H, Abraham R, Ramakrishnan L J Lipid Atheroscler. 2022; 11(3):229-249.

PMID: 36212746 PMC: 9515729. DOI: 10.12997/jla.2022.11.3.229.


TNFα priming through its interaction with TNFR2 enhances endothelial progenitor cell immunosuppressive effect: new hope for their widespread clinical application.

Barkestani M, Shamdani S, Afshar Bakshloo M, Arouche N, Bambai B, Uzan G Cell Commun Signal. 2021; 19(1):1.

PMID: 33397378 PMC: 7784277. DOI: 10.1186/s12964-020-00683-x.


Improvement in circulating endothelial progenitor cells pool after cardiac resynchronization therapy: increasing the list of benefits.

Cristovao G, Milner J, Sousa P, Ventura M, Cristovao J, Elvas L Stem Cell Res Ther. 2020; 11(1):194.

PMID: 32448383 PMC: 7245793. DOI: 10.1186/s13287-020-01713-8.


Progenitor Cells and Clinical Outcomes in Patients With Heart Failure.

Tahhan A, Hammadah M, Sandesara P, Hayek S, Kalogeropoulos A, Alkhoder A Circ Heart Fail. 2017; 10(8).

PMID: 28790053 PMC: 5809135. DOI: 10.1161/CIRCHEARTFAILURE.117.004106.


Endothelial progenitor cells in chronic obstructive pulmonary disease and emphysema.

Doyle M, Tracy R, Parikh M, Hoffman E, Shimbo D, Austin J PLoS One. 2017; 12(3):e0173446.

PMID: 28291826 PMC: 5349667. DOI: 10.1371/journal.pone.0173446.